Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (9)

« Back to Publications

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy.

Kiselev E. et al, (2026), Br J Pharmacol, 183, 1122 - 1139

ssaying the myosin super-relaxed state across muscle types, cells and proteins for understanding muscle biology and use in drug discovery.

Jones STM. et al, (2025), Nat Protoc

Targeted genetic therapies for inherited disorders that affect both cardiac and skeletal muscle.

Psaras Y. and Toepfer CN., (2024), Exp Physiol, 109, 175 - 189

Comparing the effects of chemical Ca2+ dyes and R-GECO on contractility and Ca2+ transients in adult and human iPSC cardiomyocytes.

Robinson P. et al, (2023), J Mol Cell Cardiol, 180, 44 - 57

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.

Margara F. et al, (2022), Sci Rep, 12

Human iPSC-CMs and in-silico technologies define mechanisms and accelerate targeted pharmacogenetics in hypertrophic cardiomyopathy

Margara F. et al, (2022)

CalTrack: High-Throughput Automated Calcium Transient Analysis in Cardiomyocytes.

Psaras Y. et al, (2021), Circ Res, 129, 326 - 341

Combining human-based in silico and in vitro models of inherited cardiac diseases for drug safety and efficacy evaluation

Margara F. et al, (2021), JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 111

Defining Diverse Disease Pathomechanisms Across Thick And Thin Filament Hypertrophic Cardiomyopathy Variants

Toepfer C. et al, (2021), CIRCULATION RESEARCH, 129